Synageva BioPharma presents data on cholesteryl ester storage disease at NLA annual meeting

Jun 1 2013

Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced three poster presentations at the National Lipid Association (NLA) annual meeting held in Las Vegas, Nevada, May 30- June 2, 2013, as well as a Synageva-sponsored satellite symposium held on Friday, May 31, 2013. The titles to the three posters on display during the conference are:

“Sebelipase Alfa Improves Dyslipidemia in Patients with Cholesteryl Ester Storage Disease”

"Identifying Cases of Cholesteryl Ester Storage Disease in a Tertiary Lipid Clinic", JP Kane, et al

"Dyslipidemia Profile in Cholesteryl Ester Storage Disease", R Tripuraneni, et al

"Sebelipase Alfa Improves Dyslipidemia in Patients with Cholesteryl Ester Storage Disease", R Tripuraneni, et al

Synageva-sponsored satellite symposium

During the NLA meeting, Synageva sponsored a satellite symposium entitled, "Why the Lipidologist Should Care About Lysosomal Acid Lipase (LAL) Deficiency" chaired by Daniel J. Rader, M.D., Cooper-McLure Professor of Medicine and Pharmacology, Chief, Division of Translational Medicine and Human Genetics Associate Director, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine at the University of Pennsylvania. The symposium was held May 31 at 7:30-9:00 a.m., PDT.